PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Guideline
PET
PSMA
Prostate cancer
Restaging
Staging
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
30
10
2022
accepted:
18
12
2022
pubmed:
6
1
2023
medline:
23
3
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.
Identifiants
pubmed: 36604326
doi: 10.1007/s00259-022-06089-w
pii: 10.1007/s00259-022-06089-w
pmc: PMC10027805
doi:
Substances chimiques
Gallium Radioisotopes
0
Oligopeptides
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466-1486Informations de copyright
© 2023. The Author(s).
Références
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
pubmed: 9815541
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11%3c2256::AID-CNCR22%3e3.0.CO;2-S[pii] .
doi: 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S[pii]
pubmed: 9610707
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167–72. https://doi.org/10.1007/s12253-008-9104-2 .
doi: 10.1007/s12253-008-9104-2
pubmed: 18802790
Yao V, Bacich DJ. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate. 2006;66:867–75. https://doi.org/10.1002/pros.20361 .
doi: 10.1002/pros.20361
pubmed: 16496414
Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, et al. Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Rep. 2019;27(491–501): e6. https://doi.org/10.1016/j.celrep.2019.03.036 .
doi: 10.1016/j.celrep.2019.03.036
Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 2021. https://doi.org/10.1016/j.euf.2021.06.006 .
doi: 10.1016/j.euf.2021.06.006
pubmed: 34167925
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. https://doi.org/10.1002/jcb.10661 .
doi: 10.1002/jcb.10661
pubmed: 14755683
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62.
pubmed: 14695135
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–78. https://doi.org/10.1016/j.eururo.2019.06.030 .
doi: 10.1016/j.eururo.2019.06.030
pubmed: 31345636
pmcid: 6853166
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x .
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. https://doi.org/10.1007/s00259-017-3670-z .
doi: 10.1007/s00259-017-3670-z
Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4 (45/9/1431 [pii]).
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41. https://doi.org/10.1021/jm100623e .
doi: 10.1021/jm100623e
pubmed: 20568777
pmcid: 3341619
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53. https://doi.org/10.1158/1078-0432.CCR-11-1357 .
doi: 10.1158/1078-0432.CCR-11-1357
pubmed: 22042970
pmcid: 3243762
Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. https://doi.org/10.1021/bc200279b .
doi: 10.1021/bc200279b
pubmed: 22369515
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2 .
doi: 10.1007/s00259-012-2298-2
pubmed: 23179945
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. https://doi.org/10.2967/jnumed.115.161299 . (jnumed.115.161299 [pii]).
doi: 10.2967/jnumed.115.161299
pubmed: 26294298
Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61. https://doi.org/10.2967/jnumed.115.156133 . (jnumed.115.156133 [pii]).
doi: 10.2967/jnumed.115.156133
pubmed: 25883128
Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74. https://doi.org/10.1007/s11307-015-0850-8 .
doi: 10.1007/s11307-015-0850-8
pubmed: 25896814
pmcid: 4531836
Giesel FL, Cardinale J, Schafer M, Neels O, Benesova M, Mier W, et al. (18)F-labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–30. https://doi.org/10.1007/s00259-016-3447-9 .
doi: 10.1007/s00259-016-3447-9
pubmed: 27342416
pmcid: 4969351
Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Kronke M, et al. Quantitative and qualitative analyses of biodistribution and PET image quality of a novel radiohybrid PSMA, (18)F-rhPSMA-7, in patients with prostate cancer. J Nucl Med. 2020;61:702–9. https://doi.org/10.2967/jnumed.119.234609 .
doi: 10.2967/jnumed.119.234609
pubmed: 31836686
pmcid: 7198378
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91. https://doi.org/10.2967/jnumed.112.104661 .
doi: 10.2967/jnumed.112.104661
pubmed: 23203246
Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, et al. Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med. 2018;59:1076–80. https://doi.org/10.2967/jnumed.117.204669 .
doi: 10.2967/jnumed.117.204669
pubmed: 29269569
Rauscher I, Kronke M, Konig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61:51–7. https://doi.org/10.2967/jnumed.119.229187 .
doi: 10.2967/jnumed.119.229187
pubmed: 31253741
pmcid: 6954457
Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.263262 .
doi: 10.2967/jnumed.121.263262
pubmed: 34933889
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7 .
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021. https://doi.org/10.1001/jamaoncol.2021.3771 .
doi: 10.1001/jamaoncol.2021.3771
pubmed: 34529005
pmcid: 8446902
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206:52–61. https://doi.org/10.1097/JU.0000000000001698 .
doi: 10.1097/JU.0000000000001698
pubmed: 33634707
pmcid: 8556578
Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, et al. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021;21:512. https://doi.org/10.1186/s12885-021-08026-w .
doi: 10.1186/s12885-021-08026-w
pubmed: 33962579
pmcid: 8103642
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5. https://doi.org/10.1016/j.juro.2006.10.097 .
doi: 10.1016/j.juro.2006.10.097
pubmed: 17222629
Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, et al. The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. Eur Urol. 2016;69:1142–8. https://doi.org/10.1016/j.eururo.2015.12.010 .
doi: 10.1016/j.eururo.2015.12.010
pubmed: 26749093
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74. https://doi.org/10.1016/j.ijrobp.2006.04.029 .
doi: 10.1016/j.ijrobp.2006.04.029
pubmed: 16798415
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856–63. https://doi.org/10.1001/jamaoncol.2019.0096 .
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674–82. https://doi.org/10.1158/1078-0432.CCR-20-4573 .
doi: 10.1158/1078-0432.CCR-20-4573
pubmed: 33622706
pmcid: 8382991
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, et al. (68)Ga-PSMA-11 positron emission tomography detects residual prostate cancer after prostatectomy in a multicenter retrospective study. J Urol. 2019;202:1174–81. https://doi.org/10.1097/JU.0000000000000417 .
doi: 10.1097/JU.0000000000000417
pubmed: 31233369
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. https://doi.org/10.2967/jnumed.115.154153 . (jnumed.115.154153 [pii]).
doi: 10.2967/jnumed.115.154153
pubmed: 25791990
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. https://doi.org/10.2967/jnumed.115.160382 . (jnumed.115.160382 [pii]).
doi: 10.2967/jnumed.115.160382
pubmed: 26112024
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94. https://doi.org/10.1016/S1470-2045(19)30415-2 .
doi: 10.1016/S1470-2045(19)30415-2
pubmed: 31375469
pmcid: 7469487
Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, et al. Multicenter external validation of a nomogram for predicting positive prostate-specific membrane antigen/positron emission tomography scan in patients with prostate cancer recurrence. Eur Urol Oncol. 2021. https://doi.org/10.1016/j.euo.2021.12.002 .
doi: 10.1016/j.euo.2021.12.002
pubmed: 34933814
Ruschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042–53. https://doi.org/10.1007/s00259-021-05501-1 .
doi: 10.1007/s00259-021-05501-1
pubmed: 34386839
pmcid: 8484204
Ferraro DA, Ruschoff JH, Muehlematter UJ, Kranzbuhler B, Muller J, Messerli M, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET. Theranostics. 2020;10:6082–94. https://doi.org/10.7150/thno.44584 .
doi: 10.7150/thno.44584
pubmed: 32483440
pmcid: 7255040
Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61:1793–9. https://doi.org/10.2967/jnumed.120.242180 .
doi: 10.2967/jnumed.120.242180
pubmed: 32358094
pmcid: 9364898
Han S, Woo S, Kim YJ, Suh CH. Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74:179–90. https://doi.org/10.1016/j.eururo.2018.03.030 .
doi: 10.1016/j.eururo.2018.03.030
pubmed: 29678358
Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, et al. Update from PSMA-SRT trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus. 2021;7:238–40. https://doi.org/10.1016/j.euf.2020.12.009 .
doi: 10.1016/j.euf.2020.12.009
pubmed: 33386288
N. Mottet, P. Cornford, R.C.N. van den Bergh, E. Briers, Expert Patient Advocate (European Prostate Cancer Coalition/Europa UOMO), M. De Santis, S. Gillessen, J. Grummet, A.M. Henry, T.H. van der Kwast, T.B. Lam, M.D. Mason, S. O’Hanlon, D.E. Oprea-Lager, G. Ploussard, H.G. van der Poel, O. Rouvière, I.G. Schoots. D. Tilki, T. Wiegel Guidelines Associates: T. Van den Broeck, M. Cumberbatch, A. Farolfi, N. Fossati, G. Gandaglia, N. Grivas, M. Lardas, M. Liew, E. Linares Espinós, L. Moris, P-P.M. Willemse; members of the EAU – ESTRO – ESUR –SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. MARCH. Publisher: EAU Guidelines Office. Arnhem, The Netherlands: Place published; 2022.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18. https://doi.org/10.1200/JCO.2015.64.2702 .
doi: 10.1200/JCO.2015.64.2702
pubmed: 26903579
pmcid: 4872347
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82. https://doi.org/10.1016/j.eururo.2020.09.046 .
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33039206
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62. https://doi.org/10.1016/j.eururo.2020.09.042 .
doi: 10.1016/j.eururo.2020.09.042
pubmed: 33172724
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448–54. https://doi.org/10.1158/1078-0432.CCR-19-1050 .
doi: 10.1158/1078-0432.CCR-19-1050
pubmed: 31511295
Fourquet A, Aveline C, Cussenot O, Crehange G, Montravers F, Talbot JN, et al. (68)Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact. Sci Rep. 2020;10:2104. https://doi.org/10.1038/s41598-020-58975-8 .
doi: 10.1038/s41598-020-58975-8
pubmed: 32034191
pmcid: 7005887
Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26:4551–8. https://doi.org/10.1158/1078-0432.CCR-20-0587 .
doi: 10.1158/1078-0432.CCR-20-0587
pubmed: 32527944
Weber M, Kurek C, Barbato F, Eiber M, Maurer T, Nader M, et al. PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study. J Nucl Med. 2021;62:88–91. https://doi.org/10.2967/jnumed.120.245456 .
doi: 10.2967/jnumed.120.245456
pubmed: 32444377
Farolfi A, Hirmas N, Gafita A, Weber M, Barbato F, Wetter A, et al. Identification of PCWG3 target populations is more accurate and reproducible with PSMA PET than with conventional imaging: a multicenter retrospective study. J Nucl Med. 2021;62:675–8. https://doi.org/10.2967/jnumed.120.246603 .
doi: 10.2967/jnumed.120.246603
pubmed: 32917782
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34936754
pmcid: 8446332
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804. https://doi.org/10.1016/S0140-6736(21)00237-3 .
doi: 10.1016/S0140-6736(21)00237-3
pubmed: 33581798
Hotta M, Gafita A, Czernin J, Calais J. Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263441 .
doi: 10.2967/jnumed.121.263441
pubmed: 36581376
Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115–25. https://doi.org/10.1016/S1470-2045(21)00274-6 .
doi: 10.1016/S1470-2045(21)00274-6
pubmed: 34246328
Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48:2024–30. https://doi.org/10.1007/s00259-020-05160-8 .
doi: 10.1007/s00259-020-05160-8
pubmed: 33336265
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857–65. https://doi.org/10.2967/jnumed.119.236414 .
doi: 10.2967/jnumed.119.236414
pubmed: 31732676
pmcid: 7262220
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194 .
doi: 10.2967/jnumed.116.183194
pubmed: 27765862
Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Rohrich M, et al. Response prediction of (177)Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med. 2020;61:689–95. https://doi.org/10.2967/jnumed.119.231431 .
doi: 10.2967/jnumed.119.231431
pubmed: 31653712
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016. S0302–2838(16)00011–7 [pii] https://doi.org/10.1016/j.eururo.2015.12.053 .
Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-016-3346-010.1007/s00259-016-3346-0[pii] .
doi: 10.1007/s00259-016-3346-010.1007/s00259-016-3346-0[pii]
pubmed: 27988802
pmcid: 5323462
Ferraro DA, Becker AS, Kranzbuhler B, Mebert I, Baltensperger A, Zeimpekis KG, et al. Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging. 2021;48:3315–24. https://doi.org/10.1007/s00259-021-05261-y .
doi: 10.1007/s00259-021-05261-y
pubmed: 33620559
pmcid: 8426229
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9. https://doi.org/10.1016/j.eururo.2021.08.002 .
doi: 10.1016/j.eururo.2021.08.002
pubmed: 34465492
Kallur KG, Ramachandra PG, Rajkumar K, Swamy SS, Desai I, Rao RM, et al. Clinical utility of Gallium-68 PSMA PET/CT scan for prostate cancer. Indian J Nucl Med. 2017;32:110–7. https://doi.org/10.4103/0972-3919.202255 .
doi: 10.4103/0972-3919.202255
pubmed: 28533638
pmcid: 5439210
Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, et al. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget. 2017;8:12247–58. https://doi.org/10.18632/oncotarget.14691 .
doi: 10.18632/oncotarget.14691
pubmed: 28103574
pmcid: 5355341
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-016-3435-010.1007/s00259-016-3435-0[pii] .
doi: 10.1007/s00259-016-3435-010.1007/s00259-016-3435-0[pii]
pubmed: 27913827
Soydal C, Araz M, Urun Y, Nak D, Ozkan E, Kucuk NO. Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer. Q J Nucl Med Mol Imaging. 2019. https://doi.org/10.23736/S1824-4785.19.03165-0 .
Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, et al. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol. 2018;20:484–90. https://doi.org/10.1007/s12094-017-1736-9 .
doi: 10.1007/s12094-017-1736-9
pubmed: 28795303
Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, et al. Treatment outcomes of metastasis-directed treatment using (68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09–002). Strahlenther Onkol. 2020;196:1034–43. https://doi.org/10.1007/s00066-020-01660-6 .
doi: 10.1007/s00066-020-01660-6
pubmed: 32617620
Lohaus F, Zophel K, Lock S, Wirth M, Kotzerke J, Krause M, et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? Eur Urol. 2019;75:548–51. https://doi.org/10.1016/j.eururo.2018.11.050 .
doi: 10.1016/j.eururo.2018.11.050
pubmed: 30578119
Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33:766–75. https://doi.org/10.1007/s12149-019-01387-0 .
doi: 10.1007/s12149-019-01387-0
pubmed: 31338731
Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, et al. (68)Ga-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with (223)Ra: proof of concept. J Nucl Med. 2017;58:438–44. https://doi.org/10.2967/jnumed.116.178533 .
doi: 10.2967/jnumed.116.178533
pubmed: 27660148
Seitz AK, Rauscher I, Haller B, Kronke M, Luther S, Heck MM, et al. Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–12. https://doi.org/10.1007/s00259-017-3887-x .
doi: 10.1007/s00259-017-3887-x
pubmed: 29185010
Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 2019;33:945–54. https://doi.org/10.1007/s12149-019-01404-2 .
doi: 10.1007/s12149-019-01404-2
pubmed: 31587172
Grubmuller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, et al. Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate. 2020;80:74–82. https://doi.org/10.1002/pros.23919 .
doi: 10.1002/pros.23919
pubmed: 31614001
Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing response to [(177)Lu]PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.260836 .
doi: 10.2967/jnumed.120.260836
pubmed: 33837069
pmcid: 8612198
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263072 .
Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria. J Nucl Med. 2020;61:678–82. https://doi.org/10.2967/jnumed.119.233817 .
doi: 10.2967/jnumed.119.233817
pubmed: 31806774
pmcid: 7198387
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–34. https://doi.org/10.1016/j.annonc.2020.06.011 .
doi: 10.1016/j.annonc.2020.06.011
pubmed: 32593798
Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1963–96. https://doi.org/10.1200/JCO.19.02757 .
doi: 10.1200/JCO.19.02757
pubmed: 31940221
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Cheng HH, D’Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, Morgan T, Nath S, Netto G, Penson DF, Pow-Sang JM, Reiter R, Roach III M, Rosenfeld S, Shabsigh A, Teply BA, Tward J, Valicenti R (2021) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer. Version 1.2022 — September 10, 2021. www.nccn.org/patients .
Donohoe KJ. The SNM procedure guideline for general imaging 6.0. 2010. http://s3.amazonaws.com/rdcmssnmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf . Accessed 04/01/2023.
Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019;60:950–4. https://doi.org/10.2967/jnumed.118.223099 .
doi: 10.2967/jnumed.118.223099
pubmed: 30552200
Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:632–41. https://doi.org/10.1007/s00259-019-04581-4 .
doi: 10.1007/s00259-019-04581-4
pubmed: 31732768
ESUR Guidelines on Contrast Agents. European Society of Urogenital Radiology 10.0. www.esur.org .
ACR Manual On Contrast Media. ACR Committee on Drugs and Contrast Media. ACR; 2021.
Cardinale J, Martin R, Remde Y, Schafer M, Hienzsch A, Hubner S, et al. Procedures for the GMP-compliant production and quality control of [(18)F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel). 2017;10. https://doi.org/10.3390/ph10040077 .
Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779–96. https://doi.org/10.3390/ph7070779 .
doi: 10.3390/ph7070779
pubmed: 24983957
Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018;122:783–93. https://doi.org/10.1111/bju.14374 .
doi: 10.1111/bju.14374
pubmed: 29726071
Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL, et al. Prospective intra-individual blinded comparison of [(18)F]PSMA-1007 and [(68) Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:763–76. https://doi.org/10.1007/s00259-021-05520-y .
doi: 10.1007/s00259-021-05520-y
Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL, et al. Correction to: prospective intraindividual blinded comparison of [(18)F]PSMA1007 and [(68) Ga]GaPSMA11 PET/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:789. https://doi.org/10.1007/s00259-021-05548-0 .
doi: 10.1007/s00259-021-05548-0
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550 . (jnumed.115.158550 [pii]).
doi: 10.2967/jnumed.115.158550
FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer . Accessed 1 Dec 2020
FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. Available online: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer . Accessed 27 May 2021.
http://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf . Accessed 20 Dec 2021.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215841s000lbl.pdf . Accessed 23 Mar 2022.
Australian TGA Approves Illuccix® for Prostate Cancer Imaging. Available online: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2021-PI-02388-1&d=20221028172310101 . Accessed 28 Oct 2022
(ANSM) Andsdmedpds. Protocole D’utilisation therapeutique et de Recueil D’informations ABX-PSMA-1007, 1300 MBq/mL solution injectable, substance active: [18F]PSMA-1007. 2010. http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64034289 . Accessed 28 Oct 2022.
Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893–903. https://doi.org/10.1007/s00259-020-05022-3 .
doi: 10.1007/s00259-020-05022-3
pubmed: 32949253
Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, et al. Synthesis of (68)Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced (68)Ga as exemplified by [(68)Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Protoc. 2022;17:980–1003. https://doi.org/10.1038/s41596-021-00662-7 .
doi: 10.1038/s41596-021-00662-7
pubmed: 35246649
Wielaard J, Habraken JBA, Brinks P, Lavalaye J, Boellaard R. Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation. EJNMMI Phys. 2020;7:20. https://doi.org/10.1186/s40658-020-00289-9 .
doi: 10.1186/s40658-020-00289-9
pubmed: 32297142
pmcid: 7158971
Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344–61. https://doi.org/10.1007/s00259-018-3977-4 .
doi: 10.1007/s00259-018-3977-4
pubmed: 29500480
pmcid: 5993859
Kaalep A, Burggraaff CN, Pieplenbosch S, Verwer EE, Sera T, Zijlstra J, et al. Quantitative implications of the updated EARL 2019 PET-CT performance standards. EJNMMI Phys. 2019;6:28. https://doi.org/10.1186/s40658-019-0257-8 .
doi: 10.1186/s40658-019-0257-8
pubmed: 31879795
pmcid: 6933045
Huizing DMV, Koopman D, van Dalen JA, Gotthardt M, Boellaard R, Sera T, et al. Multicentre quantitative (68)Ga PET/CT performance harmonisation. EJNMMI Phys. 2019;6:19. https://doi.org/10.1186/s40658-019-0253-z .
doi: 10.1186/s40658-019-0253-z
pubmed: 31705215
pmcid: 6841905
Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, et al. Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials. J Nucl Med. 2015;56:955–61. https://doi.org/10.2967/jnumed.115.158402 . (jnumed.115.158402 [pii]).
doi: 10.2967/jnumed.115.158402
pubmed: 25883122
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. https://doi.org/10.1007/s00259-016-3573-4 .
doi: 10.1007/s00259-016-3573-4
pubmed: 27889802
Langbein T, Wurzer A, Gafita A, Robertson A, Wang H, Arcay A, et al. The influence of specific activity on the biodistribution of (18)F-rhPSMA-7.3: a retrospective analysis of clinical positron emission tomography data. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262471 .
Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–6. https://doi.org/10.1016/j.eururo.2015.06.010 . (S0302–2838(15)00513–8 [pii]).
doi: 10.1016/j.eururo.2015.06.010
pubmed: 26116958
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43. https://doi.org/10.1016/j.juro.2015.12.025 . (S0022–5347(15)05397–5 [pii]).
doi: 10.1016/j.juro.2015.12.025
pubmed: 26682756
Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. Radiopharmaceuticals for the diagnosis and therapy of neuroendocrine differentiated prostate cancer. Curr Radiopharm. 2017;10:6–15. https://doi.org/10.2174/1874471009666161229123126 .
doi: 10.2174/1874471009666161229123126
pubmed: 28034291
Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30:e386–9. https://doi.org/10.1200/JCO.2011.41.5166 .
doi: 10.1200/JCO.2011.41.5166
pubmed: 23169519
Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014;4:60. https://doi.org/10.3389/fonc.2014.00060 .
doi: 10.3389/fonc.2014.00060
pubmed: 24724054
pmcid: 3971158
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52. https://doi.org/10.2967/jnumed.117.191031 .
doi: 10.2967/jnumed.117.191031
pubmed: 28687599
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117–36. https://doi.org/10.1007/s00259-017-3780-7 .
doi: 10.1007/s00259-017-3780-7
pubmed: 28765998
Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, et al. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. Semin Nucl Med. 2019;49:255–70. https://doi.org/10.1053/j.semnuclmed.2019.02.006 .
doi: 10.1053/j.semnuclmed.2019.02.006
pubmed: 31227049
Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-016-3360-210.1007/s00259-016-3360-2[pii] .
doi: 10.1007/s00259-016-3360-210.1007/s00259-016-3360-2[pii]
pubmed: 26996777
Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(6)(8)Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3. https://doi.org/10.1007/s00259-015-3065-y .
doi: 10.1007/s00259-015-3065-y
pubmed: 25916744
Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2. https://doi.org/10.1007/s00259-014-2766-y .
doi: 10.1007/s00259-014-2766-y
pubmed: 24756358
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.
pubmed: 10537328
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.
pubmed: 10397265
Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4. https://doi.org/10.1007/s00259-014-2915-3 .
doi: 10.1007/s00259-014-2915-3
pubmed: 25248644
Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31:696–702. https://doi.org/10.1007/s12149-017-1201-4 .
doi: 10.1007/s12149-017-1201-4
pubmed: 28831739
pmcid: 5651702
Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester HJ, et al. Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity. J Nucl Med. 2021;62:1082–8. https://doi.org/10.2967/jnumed.120.251447 .
doi: 10.2967/jnumed.120.251447
pubmed: 33277394
Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, et al. (68)Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med. 2018;59:1406–11. https://doi.org/10.2967/jnumed.117.204677 .
doi: 10.2967/jnumed.117.204677
pubmed: 29371407
Arnfield EG, Thomas PA, Roberts MJ, Pelecanos AM, Ramsay SC, Lin CY, et al. Clinical insignificance of [(18)F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05456-3 .
doi: 10.1007/s00259-021-05456-3
pubmed: 34383089
Grunig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05424-x .
doi: 10.1007/s00259-021-05424-x
pubmed: 34725726
pmcid: 8560591
Wondergem M, van der Zant FM, Broos WAM, Knol RJJ. Matched-pair comparison of (18)F-DCFPyL PET/CT and (18)F-PSMA-1007 PET/CT in 240 prostate cancer patients: interreader agreement and lesion detection rate of suspected lesions. J Nucl Med. 2021;62:1422–9. https://doi.org/10.2967/jnumed.120.258574 .
doi: 10.2967/jnumed.120.258574
pubmed: 33547211
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78. https://doi.org/10.2967/jnumed.117.198119 .
doi: 10.2967/jnumed.117.198119
pubmed: 29123012
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78–82. https://doi.org/10.1016/j.euo.2018.03.010 .
doi: 10.1016/j.euo.2018.03.010
pubmed: 31100231
Luckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96. https://doi.org/10.1186/s13550-018-0451-z .
doi: 10.1186/s13550-018-0451-z
pubmed: 30374743
pmcid: 6206308
Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14. https://doi.org/10.1186/s40644-016-0072-610.1186/s40644-016-0072-6[pii] .
doi: 10.1186/s40644-016-0072-610.1186/s40644-016-0072-6[pii]
pubmed: 27277843
pmcid: 4898465
Larson DB. Strategies for implementing a standardized structured radiology reporting program. Radiographics. 2018;38:1705–16. https://doi.org/10.1148/rg.2018180040 .
doi: 10.1148/rg.2018180040
pubmed: 30303804
Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44:1622–35. https://doi.org/10.1007/s00259-017-3725-1 .
doi: 10.1007/s00259-017-3725-1
pubmed: 28536833
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 10. J Nucl Med. 2018;59:479–85. https://doi.org/10.2967/jnumed.117.195255 .
doi: 10.2967/jnumed.117.195255
pubmed: 28887401
pmcid: 6910634
Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, et al. Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. J Nucl Med. 2019;60:511–6. https://doi.org/10.2967/jnumed.118.217653 .
doi: 10.2967/jnumed.118.217653
pubmed: 30190303
pmcid: 6448464
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, et al. Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on (18)F-DCFPyL PET/CT imaging. J Nucl Med. 2018;59:1857–64. https://doi.org/10.2967/jnumed.118.217588 .
doi: 10.2967/jnumed.118.217588
pubmed: 30190304
pmcid: 6278904
Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–38. https://doi.org/10.1007/s00259-021-05245-y .
doi: 10.1007/s00259-021-05245-y
pubmed: 33604691
pmcid: 8113168
Emmett LM, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263448 .
doi: 10.2967/jnumed.121.263448
pubmed: 36215568
pmcid: 8973290
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05882-x .
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4. https://doi.org/10.2967/jnumed.116.181800 .
doi: 10.2967/jnumed.116.181800
pubmed: 27660139
pmcid: 5209643
Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, et al. Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted (18)F-DCFPyL PET/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide. J Nucl Med. 2021;62:1430–7. https://doi.org/10.2967/jnumed.120.259069 .
doi: 10.2967/jnumed.120.259069
pubmed: 33608426
pmcid: 8724901
Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045–54. https://doi.org/10.1007/s00259-018-4079-z .
doi: 10.1007/s00259-018-4079-z
pubmed: 29980832
pmcid: 6182397
PRESCRIBING INFORMATION, Gallium Ga 68 PSMA-11 Injection, for intravenous use, Initial U.S. Approval: 2020, Reference ID: 4679258. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf . Accessed 04/01/2023
PRESCRIBING INFORMATION, PYLARIFY® (piflufolastat F 18) injection, for intravenous use, Initial U.S. Approval: 2021, Reference ID: 4802126. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf . Accessed 04/01/2023
Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, et al. Safety, biodistribution, and radiation dosimetry of (18)F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2021;62:679–84. https://doi.org/10.2967/jnumed.120.252114 .
doi: 10.2967/jnumed.120.252114
pubmed: 33067338
pmcid: 8844263